Characteristics of scheduled VST treatment failures
| Patient number . | Indication for transplant . | Conditioning intensity and graft . | GVHD prophylaxis . | EBV and CMV serostatus (donor/recipient) . | Viral load prior to VST infusion . | Transplant day at infusion . | Criteria for treatment failure . | Peak viral load by 100 d after transplant . | Additional antiviral therapy (posttransplant day therapy started) . | Status at last follow-up . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALL, CR1 | MAC Haploidentical PBSC | T-cell depletion | CMV: −/+ EBV: +/+ | Plasma BK 911 | 27 | EBV viremia | 536 198 (EBV) | Rituximab (day +94) | Dead, sepsis, day 675 |
| 9 | FA | MAC MUD PBSC | T-cell depletion | CMV: +/− EBV: +/− | Plasma BK 927 | 21 | Symptomatic BK viruria | 11 837 (BKV) | None | Alive |
| 20 | SDS | RIC MUD Marrow | CSA, MMF, abatacept | CMV: −/indeterminate EBV: +/+ | N/A | 30 | EBV viremia | 528 917 (EBV) | Rituximab (day +82), 3rd party VST (day +83) | Alive |
| 22 | β-thalassemia | MAC MUD Marrow | Tacrolimus, MMF, abatacept | CMV: +/+ EBV: −/+ | N/A | 21 | CMV viremia | 9400 (CMV) | Valganciclovir (day+57) | Alive |
| 26 | NK lympho- proliferative disorder | RIC MUD Marrow | Tacrolimus, MMF | CMV: +/− EBV: +/+ | N/A | 21 | Grade 3-4 GVHD | 308 723 (ADV) | Cidofovir (day +98) | Dead, MOF, day 199 |
| Patient number . | Indication for transplant . | Conditioning intensity and graft . | GVHD prophylaxis . | EBV and CMV serostatus (donor/recipient) . | Viral load prior to VST infusion . | Transplant day at infusion . | Criteria for treatment failure . | Peak viral load by 100 d after transplant . | Additional antiviral therapy (posttransplant day therapy started) . | Status at last follow-up . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALL, CR1 | MAC Haploidentical PBSC | T-cell depletion | CMV: −/+ EBV: +/+ | Plasma BK 911 | 27 | EBV viremia | 536 198 (EBV) | Rituximab (day +94) | Dead, sepsis, day 675 |
| 9 | FA | MAC MUD PBSC | T-cell depletion | CMV: +/− EBV: +/− | Plasma BK 927 | 21 | Symptomatic BK viruria | 11 837 (BKV) | None | Alive |
| 20 | SDS | RIC MUD Marrow | CSA, MMF, abatacept | CMV: −/indeterminate EBV: +/+ | N/A | 30 | EBV viremia | 528 917 (EBV) | Rituximab (day +82), 3rd party VST (day +83) | Alive |
| 22 | β-thalassemia | MAC MUD Marrow | Tacrolimus, MMF, abatacept | CMV: +/+ EBV: −/+ | N/A | 21 | CMV viremia | 9400 (CMV) | Valganciclovir (day+57) | Alive |
| 26 | NK lympho- proliferative disorder | RIC MUD Marrow | Tacrolimus, MMF | CMV: +/− EBV: +/+ | N/A | 21 | Grade 3-4 GVHD | 308 723 (ADV) | Cidofovir (day +98) | Dead, MOF, day 199 |
ALL, acute lymphoblastic leukemia; CSA, cyclosporine A; CR1, first complete remission; FA, Fanconi anemia; MAC, myeloablative conditioning; MMF, mycophenolate mofetil; MOF, multiorgan failure; MUD, matched unrelated donor; NK, natural killer cell; PBSC, peripheral blood stem cells; RIC, reduced intensity conditioning; SDS, Shwachman-Diamond syndrome; VST, virus-specific T cell.